Actuate Therapeutics, Inc. (ACTU) · Oct 28, 2026 · Share issuance
$10M financing — Approximately $9.96M net proceeds; 30.99M shares plus 15.49M warrants
Actuate’s financing is closed, bringing in nearly $10M for elraglusib development—but the stock-and-warrant structure makes dilution the immediate tradeoff.
Actuate is a cash-dependent, clinical-stage oncology biotech trying to move elraglusib from earlier IV studies toward an FDA-cleared oral Phase 1/2 program, with trial advancement previously tied to securing additional funding. The financing removes an immediate funding constraint, but does not add new clinical evidence. The company closed the offering on October 28 and received approximately $9.96 million net. 〔0〕
| Item | Offering terms |
|---|---|
| Common shares issued | 30,985,900 |
| Common warrants issued | 15,492,950 |
| Warrant exercise price | $0.45 |
| Potential warrant proceeds | Approximately $7.0 million |
| Net proceeds to Actuate | Approximately $9.96 million |
This is strategically useful capital, not a business inflection. The proceeds can support working capital and general corporate purposes, which should help Actuate pursue its oral elraglusib development plan; however, the filing does not earmark the cash for a specific trial, milestone, or indication. 〔1〕 The added capital therefore advances the company’s ability to operate, but leaves the timing and scope of clinical execution unresolved.
The price of that runway is substantial dilution and more potential supply. Investors received nearly 31 million new shares plus immediately exercisable warrants for another 15.5 million shares, while the underwriter also has a 45-day over-allotment option. The warrants could provide another approximately $7 million if exercised, but the filing explicitly gives no assurance that they will be.
Relative to the standing story, this is partly known rather than a surprise. The pricing was announced on October 27, so the closing itself mainly confirms that the planned capital raise completed; the new information is the finalized net cash delivered to the company. The financing is therefore a meaningful liquidity event, but not a change in the underlying clinical-risk profile.
Bottom line: Actuate bought more time to advance elraglusib, which matters for a funding-constrained biotech, but it did so through a heavily dilutive structure. The event strengthens execution capacity without proving the drug or materially changing the clinical thesis.
Oral elraglusib Phase 1/2 study initiation
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!